Gilead Sciences (NSDQ:GILD) announced that Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) offered sustained efficacy at week 240 in two Phase studies (Study 1489 and Study 1490).
The Foster City, California–based company noted that there were no cases of treatment failure as a result of viral resistance detected in the studies.
The company presented the data at the 29th Conference on Retroviruses and Opportunistic Infections.
FDA approved Biktarvy in 2018, expanding its use in 2021 to include some HIV-positive children.
“Many people living with HIV are concerned about the ability of their therapy to achieve long-term viral suppression since they will likely be on treatment for the duration of their lives,” said Dr. David Alain Wohl, professor of medicine, division of infectious diseases at the University of North Carolina at Chapel Hill, in a statement.
Gilead Sciences recently agreed to pay a 3% royalty on future U.S. sales of Biktarvy in addition to a $1.25 billion upfront payment to settle global patent infringement litigation with ViiV Healthcare.
The drug generated $7.26 billion in sales in 2020 and $8.62 billion in 2021.
Filed Under: Infectious Disease
